Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UTICORT is a topical gel formulation of betamethasone benzoate, a potent corticosteroid indicated for inflammatory and pruritic dermatological conditions. The drug works by reducing inflammation and immune response at the skin surface through corticosteroid receptor activation. It is currently in pre-launch phase under Pfizer sponsorship.
Pre-Launch
Pre-launch products require lean, focused teams during regulatory clearance; hiring accelerates post-approval for commercial build-out.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UTICORT during pre-launch offers exposure to product lifecycle management from regulatory clearance through commercial launch. This stage demands strategic cross-functional collaboration, presenting strong career development potential for professionals in commercial, medical, and market access functions.
Brand ManagerProduct Manager
Worked on UTICORT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.